Cannara Announces Conditional Approval to List on the Toronto Stock Exchange

Executive Summary

• Cannara Biotech Inc. received conditional approval to uplist its common shares from the TSX Venture Exchange to the Toronto Stock Exchange (TSX).
• Completion of the uplisting is subject to meeting TSX listing conditions; once finalized, the shares will be delisted from the TSXV and continue trading under “LOVE” on the TSX.
• The company expects enhanced visibility, greater liquidity for shareholders, and continued execution of its growth and profitability strategy.

Key Details

• Conditional approval granted by the Toronto Stock Exchange (TSX) for uplisting of Cannara’s common shares.
• Uplisting will move the ticker “LOVE” from TSXV to TSX; shares will be delisted from the TSXV upon completion.
• Final approval is contingent on satisfying specific TSX listing requirements.
• Company plans to issue a follow‑up press release once the expected commencement date for TSX trading is confirmed.
• CEO Zohar Krivorot highlighted the uplisting as validation of the company’s vision and a catalyst for increased investor visibility and liquidity.

Notable Quotes

“Today’s announcement represents a significant validation of the vision and hard work our entire team has poured into building Cannara… we look forward to completing the final listing requirements and joining the TSX, where we believe their enhanced platform will provide additional visibility to potential new investors and greater liquidity for our shareholders.” – Zohar Krivorot, Founder & CEO

Materiality Assessment: Material – Positive** (The uplisting is a material corporate event that can positively impact share liquidity, market perception, and access to capital.)